雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

BRAIN and NERVE Volume 71, Issue 11 （November 2019）

BRAIN and NERVE 71巻11号（2019年11月発行）

Japanese English

増大特集 ALS2019

ALSにおける免疫療法開発の現状と展望 Immunotherapy Against Misfolded Proteins in ALS 漆谷真 ¹ , 玉木良高 ¹ , 引網亮太 ¹ , 南山素三雄 ¹ Makoto Urushitani ¹ , Yoshitaka Tamaki ¹ , Ryota Hikiami ¹ , Sumio Minamiyama ¹ ¹滋賀医科大学内科学講座脳神経内科 ¹Department of Neurology, Shiga University of Medical Science キーワード：筋萎縮性側索硬化症 , ALS , SOD1 , TDP-43 , ミスフォールド蛋白質 , 免疫療法 , ワクチン , 抗体療法 , 一本鎖抗体 , scFv , amyotrophic lateral sclerosis , superoxide dismutase 1 , TAR DNA-binding protein 43 kDa , immunotherapy , single chain variable fragment Keyword: 筋萎縮性側索硬化症 , ALS , SOD1 , TDP-43 , ミスフォールド蛋白質 , 免疫療法 , ワクチン , 抗体療法 , 一本鎖抗体 , scFv , amyotrophic lateral sclerosis , superoxide dismutase 1 , TAR DNA-binding protein 43 kDa , immunotherapy , single chain variable fragment pp.1289-1301

発行日 2019年11月1日 Published Date 2019/11/1

DOI https://doi.org/10.11477/mf.1416201439

PDF(2483KB)

有料閲覧

Abstract 文献概要
1ページ目 Look Inside
参考文献 Reference

筋萎縮性側索硬化症（ALS）の病態において変異SOD1やTDP-43を代表とするミスフォールド蛋白質は細胞内外で多彩な病的パスウェイの原因となる。ワクチンや抗体分子を用いた免疫療法は特定の構造のみを標的とすることが可能なため有力な分子標的治療であるが，ミスフォールド蛋白質の主座が細胞内外のいずれかによってアプローチが異なり，細胞外蛋白質には全長抗体，細胞内蛋白質には一本鎖抗体（scFv）の開発研究が進んでいる。

Abstract

Protein misfolding crucially underlies the pathogenesis of amyotrophic lateral sclerosis (ALS). Mutant superoxide dismutase 1 (SOD1) and TAR DNA-binding protein 43kDa (TDP-43) are major causal proteins for familial and sporadic ALS, respectively, provoking diverse pathogenic pathways in both intracellular and extracellular environments. Of note, cell-to-cell spreading behavior is implicated in the progression of neurodegeneration, suggesting application in immunotherapies including vaccination, and antibody application as a molecular targeting therapy, due to strict antigen-specificity. Although immunotherapy of intravenous application of full-length immunoglobulin is aimed at targeting the extracellular proteins because of low access to the cytosol, it is therefore necessary to generate expression vectors for variable single chain fragments (scFv) that target intracellular proteins. Despite the advantages of scFv, such as low molecular size and the ability to apply molecular modifications adding proteolytic signals, safety and efficacy should be cautiously estimated in preclinical studies, using appropriate animal models. In ALS, we firstly succeeded in the vaccination of mutant SOD1 transgenic mice, which was followed by accumulating evidence showing the efficacy of immunization against misfolded SOD1. In TDP-43 proteinopathy, we are developing immunotherapy using intrabodies with proteolytic properties against mislocalized or aggregated forms of TDP-43 inside cells.